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BACKGROUND: Insulin-like growth factor 1 (IGF1) promotes breast cancer and disease progression. Bioavailability of IGF1 is modulated
by IGF-binding proteins (IGFBPs). IGFBP4 inhibits IGF1 activity but cleavage by pregnancy-associated plasma protein-A (PAPP-A)
protease releases active IGF1.
METHODS: Expression of IGF pathway components and PAPP-A was assessed by western blot or RT–PCR. IGFBP4 (dBP4) resistant
to PAPP-A cleavage, but retaining IGF-binding capacity, was used to block IGF activity in vivo. 4T1.2 mouse mammary
adenocarcinoma cells transfected with empty vector, vector expressing wild-type IGFBP4 or vector expressing dBP4 were implanted
in the mammary fat pad of BALB/c mice and tumour growth was assessed. Tumour angiogenesis and endothelial cell apoptosis were
assessed by immunohistochemistry.
RESULTS: 4T1.2 cells expressed the IGF1R receptor and IGFBP4. PAPP-A was expressed within mammary tumours but not by 4T1.2
cells. Proliferation and vascular endothelial growth factor (VEGF) production by 4T1.2 cells was increased by IGF1(E3R) (recombinant
IGF1 resistant to binding by IGFBPs) but not by wild-type IGF1. IGF1-stimulated microvascular endothelial cell proliferation was
blocked by recombinant IGFBP4. 4T1.2 tumours expressing dBP4 grew significantly more slowly than controls or tumours expressing
wild-type IGFBP4. Inhibition of tumour growth by dBP4 was accompanied by the increased endothelial cell apoptosis.
CONCLUSION: Protease-resistant IGFBP4 blocks IGF activity, tumour growth and angiogenesis .
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Insulin-like growth factors (IGFs) are small potent mitogenic
proteins and there is significant evidence that IGF1 promotes breast
cancer and plays a role in disease progression (Hankinson et al,
1998). The type I insulin-like growth factor receptor (IGF1R) is
overexpressed by many breast cancer cell lines and high levels of
IGF1 are associated with poor prognosis in breast cancer (Huynh
et al, 1993; Peyrat et al, 1993). IGF1 (or 2) binding results in
autophosphorylation of IGF1R and activation of PI3K (phosphati-
dylinositol-3-kinase), Akt and MAPK (mitogen-activated protein
kinase) (LeRoith et al, 1995; Saltiel and Kahn, 2001). The insulin-like
growth factor-binding proteins (IGFBPs) modulate the biological
activity of IGF, either inhibiting or potentiating its effects. At least
six IGFBPs have been identified to date. Proteolysis of the IGFBPs
plays a vital role in regulating IGF activity (Fowlkes et al,1 9 9 7 )
r e l e a s i n gb i o l o g i c a l l ya c t i v eI G F( C l e m m o n set al,1 9 9 8 ) .
IGFBP4 inhibits the activity of IGF1 and does not enhance the
actions of IGF1 under any conditions (Jones and Clemmons, 1995).
IGFBP4 is produced mainly in the liver but many other tissues,
especially neoplastic tissue, produce it (Korc-Grodzicki et al, 1993;
Lewinski et al, 2004).
IGFBP4 protease activity has been described in a variety of cell
types including placental tissue, fibroblasts and osteoblasts
(Conover et al, 1993; Durham et al, 1995). The IGFBP4 protease
is a metalloprotease, which cleaves IGFBP4 into 18 and 14kDa
fragments and its activity is IGF-dependent (Conover et al, 1995).
It was later identified as pregnancy-associated plasma protein-A
(PAPP-A) (Lawrence et al, 1999) with a cleavage site at Met
135-
Lys
136 in the mature human IGFBP4 protein (Conover et al, 1995;
Chelius et al, 2000). Although IGFBP4 inhibits the actions of IGF1,
proteolytic cleavage by PAPP-A in vivo releases biologically active
IGF from IGFBP4. In addition to PAPP-A, prostatic kallikreins,
hK2 and hK3 (prostate specific antigen), can also cleave IGFBP4
(Rehault et al, 2001).
We established that 4T1.2 mouse mammary adenocarcinoma
cells expressed IGF1R and were responsive to IGF1. We anticipated
that wild-type IGFBP4 would be unable to block IGF1 activity in
4T1.2 mammary tumours in vivo because of the presence of active
PAPP-A in mammary tissue. We hypothesised that a protease-
resistant IGFBP4, however, would inhibit 4T1.2 tumour growth by
binding IGF1 rendering it biologically inactive even in the presence
of PAPP-A. In the orthotopic 4T1.2 breast cancer model, we
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sdemonstrate that the expression of a protease-resistant IGFBP4,
where the PAPP-A cleavage site has been mutated without altering
its IGF-binding capacity, inhibited 4T1.2 tumour growth. PAPP-A
sensitive wild-type IGFBP4 had no significant effect on tumour
growth. Inhibition of tumour growth was accompanied by
increased endothelial cell apoptosis within the tumours.
MATERIALS AND METHODS
Cell culture
4T1.2 cells, murine mammary adenocarcinoma cells that prefer-
entially metastasise to bone, were a gift from Robin Anderson
(Peter MacCallum Cancer Centre, Australia.) (Lelekakis et al,
1999). 4T1.2 cells were maintained in Roswell Park Memorial
Institute (RPMI) 1640 medium, supplemented with 10% (v/v) fetal
calf serum (FCS), 100Uml
 1 penicillin, and 100mgml
 1 strepto-
mycin sulphate. MCF7 human breast adenocarcinoma cells were
maintained in Eagles Minimum Essential Medium supplemented
with 10% (v/v) FCS. Human embryonic kidney (HEK) 293 cells
were maintained in high-glucose Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% (v/v) FCS. MC3T3
osteoblasts were differentiated for 7 days in aMEM containing 10%
(v/v) FCS supplemented with 10mM b-glycerol phosphate and
50mgml
 1 ascorbic acid. Primary dNeo-Neonatal human dermal
microvascular endothelial cells (MVECs) were purchased from
Lonza (Lonza Workingham Ltd, Workingham, UK) and main-
tained in complete EGM-2MV Microvascular Endothelial Cell
Growth Medium-2 (Lonza Workingham Ltd, Workingham, UK)
(containing gentamicin, 5% (v/v) FCS, hEGF, hydrocortisone,
VEGF, hFGF-B, R
3-IGF-1 and ascorbic acid). All cell lines were
cultured at 371C in an atmosphere of 5% CO2 in air.
Effect of IGF1 on 4T1.2 cell proliferation
10
3 4T1.2 cells per well were plated in triplicate in 96-well plates,
allowed to adhere overnight, then treated with recombinant mouse
IGF1 (R&D Systems, Abingdon, UK) or IGF1 (E3R) (Upstate, Cell
Signaling Solutions, Lake Placid, NY, USA) for 48h at 0–
100ngml
 1. Following treatment, cell proliferation was assessed
using a colourimetric cell proliferation BrdU ELISA Kit (Roche
Diagnostics, Burgess Hill, UK). Proliferation was expressed relative
to untreated controls, which were taken as 100%.
Effect of IGF1 on MVEC proliferation
1500 MVEC cells per well were plated in duplicate in 96-well plates,
allowed to adhere overnight, then treated for 96h in complete
EGM-2MV medium with 50ngml
 1 recombinant human IGF-1
alone or in combination with 200ngml
 1 recombinant human
IGFBP4, or with 10ngml
 1 recombinant human VEGF alone
(IGF1, IGFBP4 and VEGF from R&D Systems). Following
treatment, 10ml of 5mgml
 1 MTT reagent (3-[4,5-Dimethyl-2-
thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide, Sigma-Aldrich,
St Louis, MO, USA) was added to each well for 4h at 371C.
Culture medium was removed, MTT was solubilised in 100ml
dimethyl sulphoxide (Sigma-Aldrich) and optical density at
570nm was recorded. Proliferation was expressed relative to
untreated controls, which were taken as 100%.
Effect of IGF1 on VEGF expression
10
3 cells per well were plated in triplicate in 96-well plates, allowed
to adhere overnight, then treated with IGF1 (R&D Systems) or
IGF1 (E3R) (Upstate, Cell Signaling Solutions) in serum-free
medium for 48h at 0–100ngml
 1. Culture supernatants were
collected and VEGF165 expression was assayed by ELISA (R&D
Systems). Total cell protein was measured by BCA assay (Pierce,
Rockford, IL, USA). VEGF165 was expressed as pgmg
 1 cell
protein.
Western blot analysis
A total of 400mg of normal mammary fat pad tissue and 4T1.2
mammary tumours was finely chopped on ice in 500ml of RIPA
buffer (25mM Tris-HCl, pH 7.4, 150mM NaCl, 1% (v/v) NP-40, 1%
(w/v) SDS, 2mM EDTA, 1/100 dilution protease inhibitor cocktail
(Sigma-Aldrich)), placed on ice for 30min, disrupted three times
(10s each) at 12000r.p.m. with a Polytron homogeniser (PT1600E,
Kinematica, Switzerland) and incubated on ice for a further
30min. Homogenate was cleared by centrifuging at 12000g for 1h
at 41C.
Conditioned medium was concentrated using 3kDa Amicon
centrifugal filters (Millipore, Billerica, MA, USA). For cell lysates,
cells were washed twice with PBS and lysed in RIPA buffer. Total
protein was quantified using the BCA assay (Pierce). A total of
25mg of protein was fractionated by 12% SDS–PAGE or using
4–20% Precise precast gels (Pierce) and transferred to nitro-
cellulose membranes. Membranes were blocked in TBST (10mM
Tris-HCl, pH 7.4, 100mM NaCl, 0.1% (v/v) Tween-20) containing
5% (w/v) non-fat powdered milk for 1h and incubated overnight at
41C with either 1:4000 rabbit anti-human IGFBP4 (Upstate) in
TBST/5% (w/v) non-fat powdered milk or 1:1000 rabbit anti-
human IGFIRb (Cell Signaling Technology Inc., Danvers, MA,
USA) in TBST/5% (w/v) BSA (bovine serum albumin). Both
antibodies also recognise the mouse protein. Membranes were
washed six times with TBST, incubated with 1:2000 horseradish
peroxidase conjugated anti-rabbit antibody (DAKO, Glostrup,
Denmark) in TBST/5% (w/v) non-fat powdered milk, for 1h, then
washed six times with TBST. Antibody complexes were detected
using Supersignal West Pico Chemiluminescent Substrate (Pierce).
PAPP-A RT–PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, Paisley,
UK) according to the manufacturer’s instructions. Briefly, samples
were homogenized in TRIzol reagent, RNA was separated using
chloroform and precipitated with isopropanol. RNA pellet was
then washed with ethanol and dissolved in RNase-free water.
SuperScript III First-Strand Synthesis System for RT–PCR
(Invitrogen, Paisley, UK) was used to generate cDNA for PCR.
PAPP-A cDNA was amplified using 50 pM forward (50-
CACTTGGGCGGTATTGTCTT-30) and reverse (50-TGGGTTGGTAT-
CATTGCAGA-30) primers, which produce a 198bp product from
mouse PAPP-A. A total of 40 cycles of 941C for 45s, 561C for 45s,
721C for 45s were carried out using AmpliTaq polymerase
(Applied Biosystems, Foster City, CA, USA). b-Actin was amplified
using mouse b-actin-specific primers (Stratagene, La Jolla, CA,
USA) by 35 cycles of 941C for 45s, 601C for 45s, 721C for 45s.
IGFBP4 cloning
Wild-type rat IGFBP4 (BP4) and protease-resistant rat IGFBP4
(dBP4) clones in pBluescript SKþ – pW12 and pSMP-8,
respectively – were a gift from Dr James Fagin, (Division of
Endocrinology, University of Cincinnati College of Medicine and
the Children’s Hospital Medical Centre, Cincinnati, OH, USA). In
dBP4, the PAPP-A cleavage site of IGFBP4, KHMAKVRDRSKMK,
was mutated to AAMAAVADASAMA, preventing proteolytic
cleavage without affecting IGF-binding capacity (Zhang et al,
2002). BP-4 and dBP-4 were excised with EcoRI, ligated into
pCMVScript and verified by sequencing. 4T1.2 cells were
transfected with pCMV, pCMV-BP4 or pCMV-dBP4 using FuGENE
6 (Roche Diagnostics).
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1.5 10
5 HEK293 cells per well were plated in six-well plates,
allowed to adhere overnight and transfected with pCMV, pCMV-
BP4 or pCMV-dBP4 using Effectene (Qiagen, Sussex, UK).
Following transfection, cells were maintained in serum-free
medium for 48h. Conditioned medium was concentrated using
3kDa Amicon centrifugal filters (Millipore) and 25mg total protein
in 20ml was incubated with IGF2 (10mgml
 1) (R&D Systems) and
rhPAPP-A (500ngml
 1) for 24h at 371C. rhPAPP-A was a gift
from Dr Claus Oxvig, University of Aarhus as described (Over-
gaard et al, 2000). Following digestion, IGFBP4 cleavage was
analysed by western blot.
In vivo model
Animals were housed in a licensed biomedical facility (RCSI,
Beaumont Hospital) and had ad libitum access to animal chow
and water. All procedures were subjected to institutional ethics
review, carried out under animal licence guidelines of the
Department of Health and Children, Ireland and in accordance with
the UK Co-ordinating Committee on Cancer Research (UKCCCR)
Guidelines for the Welfare of Animals in Experimental Neoplasia
(1998). 5 10
4 4T1.2 cells transfected with pCMV, pCMV-BP4 or
pCMV-dBP4 were implanted into the mammary fat pad of 12-week-
old female BALB/c mice. Tumours were measured with calipers on
alternate days and the mean tumour diameter (MTD) (square root of
the product of length by breadth) was calculated. In the first
experiment, mice in all groups were killed when the controls reached
an MTD of 17mm in accordance with UKCCCR Guidelines (1998).
Primary tumours were excised, and snap-frozen in OCT (Leica, UK).
In the second experiment, individual animals in each group were
killed when their tumour reached an MTD of 17mm.
Immunohistochemistry
Sections (7mm) were cut from tissues preserved in OCT com-
pound, fixed in cold acetone for 5min, cold acetone: chloroform
(1:1) for 5min and cold acetone for 5min followed by three
washes in PBS for 5min each.
Microvessel density was assessed as described previously
(Harmey et al, 2002). In brief, following staining with an antibody
to MECA32, an endothelial cell-specific marker, vessels were
counted in five high power fields of view (h.p.f.) per section ( 400
magnification, ( 40 objective and  10 ocular)) from five mice
per group.
Apoptotic endothelial cells were identified with CD31 (to
identify endothelial cells) and TUNEL (to identify apoptotic cells)
staining. Sections fixed as above, were incubated with rat anti-
mouse CD31 (BD-Pharmingen, San Jose, CA, USA) 1:400 in
protein block (5%(v/v) normal horse serum, 1%(v/v) normal goat
serum in PBS) overnight at 41C, then washed three times in PBS.
Sections were incubated with protein block for 10min, then
incubated with Texas Red conjugated goat anti-rat IgG (West
Grove, PA, USA) diluted 1:200 in protein block for 90min, and
washed four times. Apoptosis was assayed using the DeadEnd
Fluorometric TUNEL System (Promega, Madison, WI, USA)
according to manufacturers instructions. Sections were then
mounted using Prolong Gold Antifade Reagent with DAPI
(Molecular Probes, Carlsbad, CA, USA). Apoptotic endothelial
cells were counted in five high power fields of view (h.p.f.) per
section ( 400 magnification, ( 40 objective and  10 ocular))
from at least three mice per group.
Immunohistochemistry data were analysed by ANOVA with
Bonferroni post hoc correction.
RESULTS
IGF1R, IGFBP4 and PAPP-A expression by 4T1. 2 cells and
4T1.2 mammary fat pad tumours
4T1.2 cells express the IGF1R, identified by western blotting with
an antibody specific for the IGF1Rb subunit (Figure 1A). Cell
lysates from MCF7 human breast cancer cells, which have
previously been shown to express IGF1R, were used as a positive
A
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Figure 1 Expression of IGF1R, IGFBP4 and the IGFBP4 protease, PAPP-A. (A) Western blot analysis of IGF 1Rb in 4T1.2 cell lysate (lane 1). Cell lysate
from MCF7 cells is shown in lane 2 as positive control. Positions of molecular weight markers are indicated (kDa). (B) Western blot analysis of IGFBP4
expression in cell lysate (lane 1) and conditioned medium (lane 2) from 4T1.2 cells. Recombinant human IGFBP4 (10ng) is shown in lane 3 as a positive
control. Positions of molecular weight markers are indicated (kDa). (C) Western blot analysis of IGFBP4 in normal mammary fat pad (lane 3) and 4T1.2
mammary fat pad tumours (lanes 4 and 5). IGFBP4 expression in cell lysate (lane 1) and conditioned medium (lane 2) from 4T1.2 cells is shown for
reference. Positions of molecular weight markers are indicated (kDa). (D) RT–PCR of PAPP-A. PAPP-A (top panel) was amplified by RT–PCR from cDNA
prepared from the 4T1.2 mammary fat pad tumours (lanes 1, 2 and 3), 4T1.2 cells (lane 4) and MC3T3 mouse osteoblasts (lane 5). Molecular weight
markers (1Kb ladder) are shown in lane 6. b-Actin (lower panel) was amplified from all samples to control for sample quality.
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mouse and human b-subunit of IGF1R. The predicted molecular
weight for the human b-subunit is 95kDa with the mouse subunit
migrating slightly higher. 4T1.2 cells expressed IGFBP4, most of
which is secreted (Figure 1B). Cellular IGFBP4 migrated slightly
slower than the secreted IGFBP4, presumably because of the
presence of the secretion signal. IGFBP4 expression in normal
mammary fat pad tissue and 4T1.2 mammary fat pad tumours was
then examined (Figure 1C). Cell lysate and conditioned medium
from 4T1.2 cells was run alongside these samples to allow size
alignment (lanes 1 and 2, respectively). Intact cell-associated
IGFBP4 as well as IGFBP4 cleavage fragments were identified in
both normal mammary fat pad tissue (lane 3) and 4T1.2 mammary
tumours (lanes 4 and 5). PAPP-A cleaves IGFBP4 at a single site
into two fragments of 18 and 14kDa (Conover et al, 1995). The
N-ter and C-ter cleavage fragments co-migrated as previously
shown (Laursen et al, 2001). The presence of IGFBP4 cleavage
fragments suggested the presence of active PAPP-A protease in
these tissues. PAPP-A expression by 4T1.2 cells and in 4T1.2
mammary fat pad tumours was assessed by RT–PCR (Figure 1D).
cDNA from differentiated mouse osteoblast MC3T3 cells pre-
viously shown to express PAPP-A was used as positive control
(Bunn et al, 2004). Although 4T1.2 cells did not express PAPP-A, it
was expressed within normal mammary fat pad tissue as well as
4T1.2 mammary fat pad tumours in vivo, suggesting that PAPP-A
is produced by host cells within the tumours.
Cell proliferation and VEGF expression in response to
IGF1
As 4T1.2 cells expressed IGF1R, cell proliferation in response to
the IGF1 ligand was examined (Figure 2A). IGF1 had no effect on
cell proliferation. However, IGF1 (E3R), a 70 amino-acid IGF1
analogue with substitution of Arg for Glu at position 3 with
reduced affinity for all IGFBPs, significantly increased cell
proliferation at doses Z60ngml
 1. The effect of biologically
active IGF1 on the expression of the angiogenic factor, VEGF was
then examined. IGF1 at doses Z50ngml
 1 had no significant
effect on VEGF165 expression, while IGF1(E3R) significantly
increased expression of VEGF165 at doses Z50ngml
 1
(Figure 2B). These data indicate that IGFBP4 (and/or other
IGFBPs) secreted by 4T1.2 cells blocked IGF1 activity. As
biologically active IGF1 increased VEGF production by 4T1.2 cells
and has previously been shown to increase proliferation of primary
HUVEC (human umbilical vein endothelial cells) (Wu et al, 2004),
we examined the effect of IGF1 on proliferation of primary human
dermal MVECs in the absence or presence of recombinant IGFBP4
(Figure 2C). IGF1 at 50ngml
 1 increased MVEC proliferation, an
effect that was blocked by 200ngml
 1 rhIGFBP4.
Protease-resistant IGFBP4 inhibits 4T1.2 tumour growth
The in vitro data suggested that IGFBP4 would inhibit IGF1-
stimulated growth of 4T1.2 tumours by blocking its effects on
tumour cell and endothelial cell proliferation and VEGF produc-
tion. In vivo, IGFBP4 is cleaved by the protease PAPP-A to release
biologically active IGF1. We therefore examined the effects of wild-
type IGFBP4 and protease-resistant IGFBP4 expression on tumour
growth in an orthotopic model of breast cancer. Protease-resistant
IGFBP4 and wild-type IGFBP4 were subcloned into pCMVScript
under the control of the CMV constitutive promoter generating
pCMV-dBP4 and pCMV-BP4, respectively. Figure 3A shows
IGFBP4 expression by transfected 4T1.2 cells. The antibody used
recognises both wild–type- and protease-resistant IGFBP4. Clones
marked with an asterisk were used for in vivo studies. As we had
no way of differentiating endogenous and exogenous IGFBP4
expression in 4T1.2 cells, pCMV, pCMV-BP4 and pCMV-
dBP4 were transfected into HEK293 cells which do not express
IGFBP4 (data not shown). Conditioned medium collected from these
cells was treated with rhPAPP-A (500ngml
 1) in the presence of
IGF2 (10mgml
 1). Figure 3B shows that dBP4 is resistant to PAPP-A
cleavage (lane 6), whereas the wild-type BP4 is completely cleaved
(lane 4). The N-ter and C-ter cleavage fragments co-migrated as
previously shown (Figure 1C and (Laursen et al, 2001)). The doublet
band seen in the conditioned medium from dBP4-transfected
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Figure 2 Effect of IGF1 on 4T1.2 tumour cells and MVECs. (A) 4T1.2
cell proliferation in response to IGF 1 or IGF 1 (E3R). Cells were treated in
triplicate for 48h and proliferation assayed by BrdU incorporation.
Proliferation is expressed as % of control where control is taken as
100%. Data (n¼3) expressed as mean±s.e.m. and analysed by ANOVA
with LSD post hoc correction. *Po0.05 vs Control. (B) VEGF expression
by 4T1.2 cells in response to IGF 1 or IGF 1 (E3R). Cells were treated for
48h in triplicate and VEGF165 measured by ELISA. Total cell protein was
measured by BCA. Data (n¼3) expressed as mean±s.e.m. and analysed
by ANOVA with Scheffe post hoc correction. *Po0.05 vs control.
(C) Effect of IGFBP4 on IGF1-induced MVEC proliferation. Cells were
treated in triplicate for 96h with 50ngml
 1 IGF1 alone or in combination
with 200ngml
 1 IGFBP4 and proliferation assessed by MTT assay. Cells
were treated with 10ngml
 1 recombinant VEGF as positive control.
Proliferation is expressed as % of control where control is taken as 100%.
Data (n¼3) expressed as mean±s.e.m. and analysed by ANOVA with
Tukey–Kramer post hoc correction. *Po0.05 vs control;
$Po0.05 vs IGF1.
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Figure 3 Protease-resistant IGFBP4 inhibits tumour growth. 4T1.2 tumour cells were transfected with control plasmid (pCMV), plasmid expressing wild-
type IGFBP4 (pCMV-BP4) or plasmid expressing protease-resistant IGFBP4 (pCMV-dBP4). (A) Western blot showing IGFBP4 expression by control cells
(lane 1) and single cell clones expressing dBP4 (lanes 2–5) or BP4 (lanes 6–8). Clones marked with an asterisk were used for in vivo studies. (B) HEK293T
cells, which do not express endogenous IGFBP4, were transfected with pCMV (lanes 1þ2), pCMV-BP4 (lanes 3þ4) or pCMV-dBP4 (lanes 5þ6).
Conditioned medium was treated with rhPAPP-A in the presence of IGF2 for 24h ( ; untreated, þ; PAPP-A-digested). Intact IGFBP4 and cleavage
fragments were identified by western blot. (C) Tumour growth curve. 4T1.2 tumour cells transfected with control plasmid (pCMV), plasmid expressing wild-
type IGFBP4 (pCMV-BP4) or plasmid expressing protease-resistant IGFBP4 (pCMV-dBP4) were implanted into the mammary fat pad of BALB/c mice (n¼7
per group). Tumour diameter was measured on alternate days. Data (n¼7) expressed as mean±s.e.m. and analysed by ANOVA with LSD post hoc
correction. *Po0.05 dBP4 vs pCMV or BP4. Data representative of two independent experiments. (D) Kaplan–Meier plot showing increased time to reach
a mean tumour diameter (MTD) of 17mm in mice with tumours expressing dBP4 relative to mice with tumours transfected with pCMV or BP4 (w
2¼16.4,
Po0.0001). Data representative of two independent experiments.
B A
D C
Figure 4 Angiogenesis in 4T1.2 mammary fat pad tumours. Sections were stained with anti-MECA32 to identify blood vessels. Negative control shown in
(A). Representative sections stained for MECA32 from the mammary fat pad tumours transfected with (B) empty vector (pCMV), (C) plasmid expressing
wild-type IGFBP4 (pCMV-BP4) or (D) plasmid expressing protease-resistant IGFBP4 (pCMV-dBP4). (Original magnification,  400).
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as reported previously (Laursen et al, 2001).
4T1.2 cells transfected with pCMV, pCMV-BP4 or pCMV-dBP4
were implanted into the mammary fat pad of BALB/c mice.
After 30 days tumours transfected with pCMV-dBP4
were significantly smaller (10.45±0.76mm) than tumours
transfected with pCMV-BP4 (15.26±0.87mm), or pCMV
(15.55±2.29mm) (Figure 3C). In this experiment all mice were
killed when tumours in the control group reached an MTD of
17mm in accordance with UKCCCR guidelines (1998). In a second
experiment, time to reach an MTD of 17mm was used as a
surrogate end point in accordance with UKCCCR guidelines
(1998). Tumours transfected with pCMV-dBP4 took significantly
longer to reach an MTD of 17mm (41.7±2.2 days) than mice-
bearing tumours transfected with pCMV (32±5.9 days) or pCMV-
BP4 (32.6±2.5 days) (Figure 3D).
Tumour angiogenesis
Microvessel density in the mammary fat pad tumours transfected
with pCMV (empty vector), wild-type IGFBP4 (BP4) or PAPP-A-
resistant IGFBP4 (dBP4) was scored following MECA32 immuno-
histochemistry (Figure 4). Although there was no statistically
significant difference in microvessel density between the different
groups (P¼NS, ANOVA with Bonferroni post hoc correction), the
vessels within tumours expressing PAPP-A-resistant IGFBP4 (D),
appeared to be of poor quality, with patchy staining suggesting a
discontinuous endothelium and expanded cell cytoplasm; vessels
were also occluded with no lumen visible, compared with tumours
transfected with pCMV (B) or pCMV-BP4 (C). Endothelial cell
apoptosis was then examined using a double stain for CD31 (to
identify endothelial cells) and TUNEL (to identify apoptotic cells)
(Figure 5). Tumours expressing PAPP-A-resistant IGFBP4 (C) had
significantly higher numbers of apoptotic endothelial cells
(6.97±3.26s.e.m/h.p.f.) than tumours transfected with pCMV
(0.90±0.50s.e.m/h.p.f.) or pCMV-BP-4 (1.20±0.95s.e.m./h.p.f.) (D).
DISCUSSION
In vivo the activity of IGF is regulated by the IGF-binding proteins,
which function to either enhance or inhibit the mitogenic activities
of IGF1 (Jones and Clemmons, 1995). The majority of IGF is
synthesised within the liver and transported in the bloodstream
bound to the IGFBPs. When bound to IGFBP4, IGF1 is biologically
inactive but IGFBP4 can be cleaved by the IGFBP4-specific
protease, PAPP-A, to release active IGF1 (Conover et al, 2004).
4T1.2 cells expressed the IGF1R and IGFBP4, but not the IGFBP4
protease PAPP-A, although PAPP-A was expressed within 4T1.2
mammary fat pad tumours. IGFBP4 cleavage fragments were
identified in 4T1.2 mammary fat pad tumour tissue but not in
cultured 4T1.2 cells or conditioned medium, suggesting that PAPP-
A within the tumours was produced by host cells. Within the
tumour environment, it is likely that the secretion of IGFBP4 in the
presence of the IGFBP4 protease (produced by host cells, such as
fibroblasts and osteoblasts) provides a steady supply of IGF1 to the
tumour to support its growth and angiogenesis. IGF1(E3R), a
recombinant form of IGF1, which is resistant to IGFBP binding
and therefore retains its activity even in the presence of IGFBPs,
increased 4T1.2 cell proliferation and production of the angiogenic
factor, VEGF. Wild-type IGF1 did not increase 4T1.2 cell
proliferation and had no effect on VEGF expression suggesting
that the IGF1 is bound by IGFBP4 (and/or other IGFBPs) secreted
by the 4T1.2 cells and rendered biologically inactive, while
IGF1(E3R) remains unbound and thus biologically active. In
addition to its effects on 4T1.2 tumour cells, IGF1 stimulated
growth of human dermal MVECs, an effect that was blocked by
recombinant IGFBP4. These data indicated that IGF1 would
promote angiogenesis and that IGFBP4 could block IGF1-
stimulated angiogenesis.
We then examined the effect of IGF1 blockade on growth of
4T1.2 mammary tumours in vivo. The approach we used was to
transfect 4T1.2 cells with a protease-resistant IGFBP4. The 4T1.2
orthotopic model used here arose from a spontaneous mammary
tumour in a BALB/c mouse and spontaneously metastasises to lung
and bone recapitulating breast tumour tissue microenvironment
and cell–cell interactions (Lelekakis et al, 1999). It is therefore a
clinically relevant model, which reflects the behaviour of human
breast cancer. The protease-resistant IGFBP4 clone used (dBP4)
was previously shown to be resistant to cleavage by a smooth
muscle cell-derived protease, but its binding affinity for IGF1 was
equivalent to wild-type IGFBP4 (Zhang et al, 2002). Previous
studies had demonstrated that this dBP4 construct was resistant to
cleavage by a protease present in conditioned medium from
smooth muscle cells, but did not unequivocally show that the
protease was PAPP-A (Zhang et al, 2002). We demonstrated that
this construct was resistant to cleavage by recombinant PAPP-A.
IGF will therefore remain bound to this IGFBP4 and inactive even
in the presence of PAPP-A. 4T1.2 cells transfected with pCMV
(empty vector), pCMV-BP4 (plasmid expressing wild-type
IGFBP4) or pCMV-dBP4 (plasmid expressing protease-resistant
IGFBP4) were implanted into the mammary fat pad of BALB/c
mice. Tumours expressing protease-resistant IGFBP4 grew sig-
nificantly more slowly than tumours transfected with pCMV or
pCMV-BP4 (measured as time to reach an MTD of 17mm). As
IGF1 increased VEGF production by the 4T1.2 cells and stimulated
MVEC proliferation, we anticipated that an antiangiogenic effect
might underlie this inhibition of tumour growth. We therefore
examined microvessel density and morphology within the tumours
by MECA32 staining. Although there was no statistically significant
difference in vessel number in the tumours of all three groups at
the time point examined, vessels in tumours expressing PAPP-A-
resistant IGFBP4 were of poorer quality than in the other groups
with patchy staining and occluded lumen. A similar effect
was previously observed in tumours treated with the angiogenesis
inhibitor, alphastatin, where vessels also had a discontinuous
endothelial cell wall and occluded lumen (Staton et al, 2004).
Tumour sections were then stained with CD31 and TUNEL
to identify apoptotic endothelial cells. There were almost no
apoptotic endothelial cells in control tumours or those expressing
wild-type IGFBP4, but there were large numbers of
apoptotic endothelial cells in the tumours expressing protease-
resistant IGFBP4. Our data clearly show that expression of PAPP-
A-resistant IGFBP4 results in endothelial cell apoptosis within the
tumours and inhibition of tumour growth. Although we saw
increased endothelial cell apoptosis in tumours expressing
protease-resistant IGFBP4, this was not reflected in reduced
microvessel density. This was probably because at the time point
analysed non-transfected cells would likely predominate within the
tumour with a concomitant decrease in dBP4 expression and
regrowth of vessels.
In contrast to our findings in an orthotopic model of breast
cancer where wild-type IGFBP4 had no effect on tumour growth,
wild-type IGFBP4 inhibited tumour growth in non-orthotopic
murine models of colon cancer and prostate cancer where
transfected cells were implanted subcutaneously (Damon et al,
1998; Durai et al, 2007). However, subcutaneous expression of the
PAPP-A protease may be quite different to that in either the colon
or the prostate gland. Our data show that PAPP-A is present and
active in both normal mammary tissue and 4T1.2 mammary fat
pad tumours where the PAPP-A is produced by host cells within
the tumours. Therefore, in the mammary tissue at least, the
interaction between the tumour cells and associated host cells is
important for PAPP-A-mediated cleavage of IGFBP4 and therefore
control of IGF bioavailability and activity. The importance of using
orthotopic mouse models in cancer studies has been highlighted
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srecently (Fidler, 2006). Tumour microenvironment plays a critical
role in tumour growth, particularly angiogenesis and metastasis,
both of which are regulated by host factors as well as tumour
factors (Fidler, 2003). As PAPP-A is expressed by fibroblasts and
osteoblasts, host cells in and around tumours are likely to play an
important role in proteolysis of IGFBP4 (Conover et al, 1993;
Durham et al, 1995).
Wild-type IGFBP4 may paradoxically increase tumour growth by
serving as a reservoir of IGF1. Indeed, systemic administration of
wild-type IGFBP4 increased bone formation parameters (osteocal-
cin, alkaline phosphate) in mice by increasing IGF bioavailability
(Miyakoshi et al, 2001). The approach described here – PAPP-A-
resistant IGFBP4 – will inhibit IGF activity even in the presence of
the PAPP-A protease and there is some evidence that PAPP-A plays
a role in human breast cancer progression (Kuhajda et al,1 9 8 5 ) .
There are a number of strategies to block IGF under investigation,
some of which are in clinical trials. An antibody, aIR3, directed
against the IGF receptor, IGF1R, blocked IGF activity and tumour
growth in xenograft models of human breast cancer, but the
antibody had some agonist activity and cross-reactivity with the
insulin receptor (Kato et al, 1993). Insulin-like growth factor
antagonists which act by blockade of interactions at the IGF1R
may also significantly alter insulin action at the insulin receptor, a
serious and unacceptable side effect. As multiple IGF receptors exist,
targeting IGF itself is likely to be more effective than targeting IGF1R.
The IGFBPs are specific for the IGFs and should not affect
insulin signalling. IGFBP2 and IGFBP3 have been examined as
approaches to block IGF signalling. As the IGFBPs bind IGF with
higher affinity than IGFR1, they should effectively compete with
the receptor for IGF ligand binding (Clemmons, 1997). rhIGFBP3
(recombinant human IGFBP3) was shown to potentiate the activity
of Herceptin against MCF7 xenografts engineered to overexpress
HER2 (Jerome et al, 2006). Unlike IGFBP4, which is always
inhibitory, other IGFBPs can either inhibit or potentiate IGF
activity depending on the context and have IGF-independent
effects as well as IGF-dependent activity. Under certain conditions
IGFBP3 increased IGF-dependent cell survival and proliferation,
possibly by enhanced delivery of IGF1 to IGF1R (De Mellow and
Baxter, 1988). IGFBP3 acts as the major carrier of IGF1 in the
circulation where it exists as a complex with the ALS (acid labile
subunit). This complex acts as a reservoir of IGF1, which can be
mobilised by proteolysis of IGFBP3. This complex does not cross
the endothelial barrier and complex formation with ALS may
impair delivery of rIGFBP3 to tumour tissue (Payet et al, 2004). We
believe that our approach using a protease-resistant IGFBP4 to
block IGF activity is superior to those described above, as it
inactivates IGF1, is small enough (24–32kDa) to cross the
endothelial barrier and should have a long half-life in vivo due
its resistance to the PAPP-A protease. In addition to the data
presented here, a protease-resistant IGFBP4 was recently shown to
inhibit IGF and therefore neointimal expansion in a model of
neointimal hyperplasia (Nichols et al, 2007). It is a relatively small
molecule compared with antibody therapies, and hence may
penetrate tumours more effectively. The data presented here
showing that a protease-resistant IGFBP4 blocks IGF activity and
therefore tumour growth and angiogenesis, suggests that protease-
resistant IGFBP4 may have value as a novel breast cancer
treatment. We are currently investigating the therapeutic potential
of recombinant protease-resistant IGFBP4 in breast cancer.
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Figure 5 Protease-resistant IGFBP4 increases endothelial cell apoptosis. Sections of 4T1.2 mammary fat pad tumours transfected with (A) empty vector
(pCMV), (B) plasmid expressing wild-type IGFBP4 (pCMV-BP4) or (C) plasmid expressing protease-resistant IGFBP4 (pCMV-dBP4) were stained for CD31
(to identify blood vessels), and TUNEL (to identify apoptotic cells). Red: CD31 positive, Green: TUNEL positive and Blue: nuclei stained with DAPI (original
magnification  400). (D) Apoptotic endothelial cells were counted in five high power fields of view (h.p.f.) per section from at least three mice per group.
Data expressed as mean±s.e.m and analysed by ANOVA with Bonferroni post hoc correction. *Po0.05 protease-resistant IGFBP4 (dBP4) vs empty vector
or wild-type IGFBP4 (BP4).
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